The Board had approved standalone Annual Audited Financials Results for the Financial Year ended 2024-2025
Awaiting price reaction for this filing.
Blueblood Ventures' Board, at its meeting on 29 May 2025, approved the standalone audited financial results for the financial year ended 31 March 2025. Statutory auditor KRA & Associates issued an unqualified (unmodified) opinion on the results. Total revenue rose to Rs 80.08 lakhs (FY24: Rs 53.93 lakhs), helped by a sharp jump in other income to Rs 30.06 lakhs from Rs 2.78 lakhs, while revenue from operations slipped slightly to Rs 50.02 lakhs. Despite higher revenue, profit after tax fell sharply to Rs 0.59 lakhs (FY24: Rs 2.44 lakhs) and basic EPS dropped to Rs 0.02 from Rs 0.08. The auditor flagged three emphasis-of-matter items: unconfirmed long-term advances of Rs 5,656.71 lakhs treated as recoverable, 247 Zero Optional Convertible Debentures (out of 4,149 units worth Rs 4,149 lakhs) wrongly transferred to a third party, and Rs 1.61 lakhs in TDS provisions neither paid nor filed. The balance sheet shows long-term borrowings unchanged at Rs 9,400 lakhs, while cash from operations was negative at Rs -320.73 lakhs.
Profitability deteriorated even as topline grew, with EPS nearly cut by three-quarters and operating cash flow deeply negative, signalling weak core earnings quality. The auditor's emphasis-of-matter items — particularly the large unconfirmed advances and the misallocation of debentures to an unknown party — are red flags worth monitoring. For shareholders, this is a small, thinly-traded, heavily borrowed company with marginal profits and several governance concerns.